Loading resource…

European Renal Association (ERA) Immunonephrology Working Group
Lupus nephritis treatment currently relies on glucocorticoids and antiproliferative agents, which often fall short due to toxicity and incomplete efficacy. The document outlines how recent insights into the disease's pathophysiology can inform new treatment paradigms that focus on disease modification. It reviews various emerging therapies targeting specific immune pathways to improve patient outcomes and prevent disease progression.
No account needed